Artiva Biotherapeutics, Inc. (ARTV)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	n/a
Revenue (ttm)	32.75M
Net Income (ttm)	-25.97M
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About ARTV

Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patient’s own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient’s treatment location, making them what we believe to be “off-the-shelf.” Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell ther...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 81
• Stock Exchange: NASDAQ
• Ticker Symbol: ARTV

Financial Performance

Financial numbers in USD